bemnifosbuvir bemnifosbuvir bemnifosbuvir (at-527, ro7496998) is an antiviral drug invented by atea pharmaceuticals and licensed to roche for clinical development, a novel nucleotide analog prodrug originally developed for the treatment of hepatitis c. at-527 is the orally bioavailable hemisulfate salt of at-511, which is metabolised in several steps to the active nucleotide triphosphate at-9010, acting as an rna polymerase inhibitor and thereby interfering with viral replication. at-527 has been researched for the treatment of coronavirus diseases such as that produced by sars-cov-2. it showed good results in early clinical trials but had inconsistent results at later stages, so the planned phase 3 trials are being redesigned and results are not expected until late 2022. bemnifosbuvirclinical dataother namesat-527, at-511legal statuslegal status us: investigational new drug identifiers iupac name propan-2-yl (2s)-2--4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate cas number1998705-64-8 y 2241337-84-6 (hemisulfate)pubchem cid122527455chemspider112747221unii7um3sql968keggd12255chemical and physical dataformulac24h33fn7o7pmolar mass581.542 g·mol−13d model (jsmol)interactive image smiles c(c(=o)oc(c)c)np(=o)(oc1(((o1)n2c=nc3=c(n=c(n=c32)n)nc)(c)f)o)oc4=cc=cc=c4 inchi inchi=1s/c24h33fn7o7p/c1-13(2)37-21(34)14(3)31-40(35,39-15-9-7-6-8-10-15)36-11-16-18(33)24(4,25)22(38-16)32-12-28-17-19(27-5)29-23(26)30-20(17)32/h6-10,12-14,16,18,22,33h,11h2,1-5h3,(h,31,35)(h3,26,27,29,30)/t14-,16+,18+,22+,24+,40?/m0/s1key:oislshlaxhalqz-heoqurlssa-n